中药防治疲劳作用机制的研究进展

疲劳是亚健康的典型表现,会导致身体发生一系列的生理变化。长期疲劳如不及时缓解,可诱发心血管功能障碍、精神障碍等严重病理反应。中药为防治疲劳、减缓继发性疾病提供了可靠的临床实践,具有抗疲劳作用的天然药物种类丰富,为开发利用新型抗疲劳药物提供崭新领域。通过对疲劳的认识、中药与天然药物防治疲劳的复杂机制进行综述,为揭示中药干预疲劳提供理论依据,也为开发具有抗疲劳潜力的新产品提供指导。     

淫羊藿总黄酮对成骨细胞增殖的影响

为探索中药淫羊藿防治骨质疏松症的作用机理，采用血清细胞培养的方法，观察淫羊藿总黄酮对动物成骨细胞增殖的影响。结果显示淫羊藿总黄酮能明显促进成骨细胞数量增殖(P＜0．05)，增加碱性磷酸酶活性(P＜0．01)，降低培养基中钙含量(P＜0．05)。由此推测淫羊藿具有较强的防治骨质疏松症的作用。     

二子阳宝的药理实验研究

二子阳宝能明显提高去势雄性小鼠副性器官和提肛肌指数；明显增加性交配功能；并能增强肾阳虚小鼠的耐缺氧，抗疲劳能力。     

Clinical Yi-guan decoction for liver cirrhosis: A protocol for systematic review and meta analysis

Background:At present, Liver Cirrhosis (LC) is common in most later liver and gallbladder diseases that its morbidity and mortality seriously affect human health. The limitation and effectiveness of western medicine on LC have become a huge clinical challenge. However, a large number of clinical studies have shown that Yi-guan decoction has become a complementary treatment for LC. Therefore, this systematic review will aim to explore the safety and feasibility of Yi-guan decoction in the treatment of LC.Methods:We will conduct a comprehensive literature search in Medline, PubMed, Cochrane Database of Systematic Reviews, Embase, Chinese Biomedical Literatures Database, China National Knowledge Infrastructure, Wang Fang Database, Chinese Scientific Journal Database from inception to December 2020 without any language restriction, In addition, relevant literature will be searched manually. The main subject terms searched: “Yi-guan decoction” “cirrhosis” “LC”. Data entry will be performed by 2 researchers separately. Primary outcomes will be concluded: Liver function indicators: Total bilirubin, Alanine transaminase, Aspartate aminotransferase, etc. Secondary outcome indicators: Total effective rate, Nutrition index, Survival analysis, Adverse events; All randomized controlled trials collected in this study will be evaluated and rated using the Cochrane risk-of-biasassessment tool. Meta-analysis will be performed using RevMan 5.4.0 software. The heterogeneity test will be conducted between the studies, P < .1 and I² > 50% are the thresholds for the tests. Using solid effect model or random effect model will be based on its heterogeneity value.Results:This systematic review provides a theoretical basis for Yi-guan decoction to treat LC, we will report this result soon.Conclusion:This study will explore Yi-guan decoction can will be used as one of the non drug therapies to prevent or treat LC.Trial registration number:INPLASY2020120114.     

运脾润肠法对慢传输型功能性便秘结肠动力的影响

[目的]观察中医运脾润肠法治疗慢传输型便秘(STC)的临床疗效及对血清一氧化氮(NO)、血浆P物质(SP)水平、结肠动力的影响.[方法]选择确诊为STC患者90例按2∶1比例随机分为2组,治疗组(应用秘通治疗)60例,对照组(莫沙必利治疗)30例,并设正常对照(正常)组30例.采用放射免疫法(RIA)测定2组治疗前、后空腹血清NO和血浆SP水平,并与正常组测得值对比.并比较2组治疗前、后的结肠通过时间(GITT).[结果]治疗组临床症状总有效率为93.3%,对照组为73.3%(P＜0.05).治疗前,2组血浆SP水平比正常组显著降低,血清NO水平比正常组显著增高;治疗后2组NO及SP水平均有显著改善,与治疗前比较差异有统计学意义(P＜0.05).但治疗组治疗后NO及SP与正常组比较P＞0.05,而对照组治疗后NO及SP与正常组比较P＜0.05.结果表明秘通、莫沙必利均可明显降低血清NO及升高血浆SP水平,而治疗组的效果优于对照组.治疗前2组GITT示48 h后停留在右半结肠或横结肠的标志物超过80%,用药后标志物显著减少并接近正常,但治疗组减少情况优于对照组.[结论]中医运脾润肠法治疗STC患者疗效显著,能缩短GITT、调节血清NO和血浆SP水平,推动肠道蠕动,促进肠道排空,达到改善患者临床症状的目的.     

疏肝润肠方防治慢传输型便秘可能机制及效应靶点的探讨

[目的]探讨疏肝润肠方干预慢传输型便秘可能机制及效应靶点.[方法]60只SPF级Balb/c雄性小鼠,按体质量随机分为:正常组、模型组、治疗组(含低、中、高剂量亚组).除正常组外,模型组、治疗组均以复方地芬诺酯灌胃制模.观察所有小鼠排便时间、排便次数及粪重,应用免疫组化SABC法检测Cajal细胞标志物C-kit表达,实时荧光定量PCR技术检测血浆中P物质(SP)和血管活性肠肽(VIP) mRNA表达变化.[结果]模型组大便次数减少、排便时间延长、粪便少而且硬;治疗组较模型组大便次数增加、排便时间缩短、大便性状偏软(P＜0.05).与正常组比较,模型组小鼠结肠黏膜Cajal细胞阳性分布面积及数目减少(P＜0.05).模型组小鼠结肠SP、VIP mRNA表达呈下降趋势;治疗组小鼠结肠SP、VIP mRNA表达呈上升趋势(P＜0.05).[结论]疏肝润肠方可能通过调控SP及VIP的分泌,从而缩短慢传输型便秘小鼠排便时间、增加排便次数及便重、促进小鼠粪便软化,增加肠推进,促进小肠的传输功能而发挥其治疗慢传输型便秘的药效.     

基于数据挖掘和网络药理学探究含黄连方剂治疗溃疡性结肠炎的配伍规律及作用机制

目的基于现代信息技术,分析以黄连Coptidis Rhizoma为核心治疗溃疡性结肠炎(ulcerative colitis,UC)的用药特点及规律,并阐明含黄连核心药物组治疗UC的分子机制,为其实验验证及新型方剂的研发奠定基础。方法运用Apriori关联规则分析用于治疗UC的含黄连方剂,设置同时满足支持度≥0.25,置信度≥0.9且提升度≥1的药对为含黄连核心药物组,利用TCMSP、HERB和TCMID数据库检索活性成分并收集相应靶点,在GeneCard和OMIM数据库中以"ulcerative colitis"为关键词检索疾病靶点,运用Cytoscape 3.7.1软件构建"中药-成分-潜在靶点"网络图,通过STRING11.0构建蛋白-蛋白相互作用(protein-protein interaction,PPI)网络,并利用"微生信在线"网站对潜在靶点进行京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路可视化,采用分子对接软件AUTODOCK 4对关键靶点和成分进行对接验证。结果数据库筛选得到161首目标方剂,主要涉及72味药;关联规则分析结果提示黄连与木香、甘草、白术、茯苓、当归是具有强关联性的5组药对,这6味核心药物一共含有144种成分、潜在靶点165个,其中有83个靶点分布在骨髓和淋巴组织,关键靶点有31个,包括丝氨酸/苏氨酸激酶1(serine/threonine kinase 1,AKT1)、肿瘤蛋白P53(tumor protein P53,TP53)、丝裂原活化蛋白激酶1(mitogen-activated protein kinase 1,MAPK1)、白细胞介素-6(interleukin-6,IL-6)、MAPK8。KEGG分析结果显示磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(protein kinase B,Akt)、IL-17、晚期糖基化终产物及其受体(advanced glycation end products-receptor advanced glycation end products,AGE-RAGE)等通路与含黄连核心药物组治疗UC密切相关。分子对接结果显示受体蛋白与中药成分的对接活性好,作用较稳定且与原配体的结合能相近,其中β-谷甾醇与原癌基因JUN具有最低的结合能。结论初步分析了含黄连方剂治疗UC的配伍规律,并且在分子水平揭示了含黄连核心药物组治疗UC的机制,为后续含黄连方剂治疗UC的开发提供了理论基础。     

Metabolomics in the development and progression of rheumatoid arthritis: A systematic review

ObjectiveA systematic review and analysis of data from several rheumatoid arthritis metabolomics studies attempts to determine which metabolites can be used as potential biomarkers for the diagnosis of rheumatoid arthritis and to explore the pathogenesis of rheumatoid arthritis.MethodsWe searched all the subject-related documents published by EMBASE, PubMed, Web of Science, and Cochrane Library from the database to the September 2019 publication. Two researchers independently screened the literature and extracted the data. QUADOMICS tool was used to assess the quality of studies included in this systematic review.ResultsA total of 10 studies met the inclusion criteria of systematic review, including 502 patients with rheumatoid arthritis and 373 healthy people. Among them, the biological samples utilised for metabolomic analysis include: serum (n = 8), urine (n = 1) and synovial fluid (n = 1). Some metabolites play an important role in rheumatoid arthritis: glucose, lactic acid, citric acid, leucine, methionine, isoleucine, valine, phenylalanine, threonine, serine, proline, glutamate, histidine, alanine, cholesterol, glycerol, and ribose.ConclusionsMetabolomics provides important new opportunities for further research in rheumatoid arthritis and is expected to elucidate the pathogenesis of rheumatoid arthritis that has not been fully understood before.     

绞股蓝的药理作用及临床治疗高脂血症研究概况

绞股蓝的主要药效成分是绞股蓝皂苷,具有非常广泛的药理作用,其在治疗高脂血症上也具有很好的疗效。本文概述了绞股蓝的药理作用及临床治疗高脂血症方面的研究概况,为绞股蓝的进一步研究开发和临床用药提供思路和参考。     

植物空心胶囊的研究进展

目前我国药用空心胶囊中绝大数为动物明胶空心硬胶囊。由于明胶的原料来源复杂、质量难控,这决定其存在诸多难以克服的性能及安全方面的缺陷。全球动物疫情频繁爆发、胶囊铬超标事件,使明胶空心胶囊面对前所未有的信任危机。因此,寻求质量更为可控的胶囊显得很有必要性,笔者综述了植物空心胶囊研究进展以期提供有益参考。